Amgen Inc (AMGN)
Cash ratio
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 9,129,000 | 11,973,000 | 10,944,000 | 7,629,000 | 7,989,000 |
| Short-term investments | US$ in thousands | — | — | 10,944,000 | 1,676,000 | 48,000 |
| Total current liabilities | US$ in thousands | 25,489,000 | 23,099,000 | 18,392,000 | 15,687,000 | 12,184,000 |
| Cash ratio | 0.36 | 0.52 | 1.19 | 0.59 | 0.66 |
December 31, 2025 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($9,129,000K
+ $—K)
÷ $25,489,000K
= 0.36
Peer comparison
Dec 31, 2025
Company name
Symbol
Cash ratio
Amgen Inc
AMGN
0.36
AbbVie Inc
ABBV
—
Biogen Inc
BIIB
1.14
Bristol-Myers Squibb Company
BMY
0.46
Eli Lilly and Company
LLY
0.12
Johnson & Johnson
JNJ
0.49
Merck & Company Inc
MRK
—
Pfizer Inc
PFE
—